You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 基石藥業(2616.HK)急漲超5% avapritinib新藥上市申請在香港獲受理
格隆匯 05-14 15:51
格隆匯5月14日丨基石藥業(2616.HK)尾盤快速拉昇漲超5%,現報10.28港元,總市值121.5億港元。基石藥業12日公佈,avapritinib新藥上市申請在香港地區獲受理,將用於治療PDGFRAD842V突變無法切除或轉移性胃腸道間質瘤成人患者。是一款強效、高選擇性口服KIT和PDGFRA抑制劑。此外,日前公司精準治療產品艾伏尼布(ivosidenib)獲美國FDA優先審評用於治療膽管癌。興業證券此前表示,公司產品收穫期已到來,管線2.0持續推進。整體來看,公司在研發、BD、生產、商業化等方面的綜合能力不斷提升,建議積極關注。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account